For decades, one of the most persistent challenges in outpatient medicine has also been one of the most familiar: a patient presents with an acute respiratory illness, symptoms overlap across etiologies, the clinical examination does not clearly establish whether the process is bacterial or non-bacterial, and a treatment decision must be made before definitive information is available.

Does the patient need an antibiotic?

Or is the more appropriate course to withhold one?

The problem is not a lack of clinical expertise. It is that acute respiratory infections frequently present with nonspecific symptoms, while many commonly used respiratory diagnostics answer a different question: which pathogen is present?

That distinction matters.

Antimicrobial stewardship programs have spent years developing prescribing guidelines, clinician education, EHR interventions, audit-and-feedback programs, and other strategies intended to reduce unnecessary antibiotic exposure.

Yet the prescribing decision still occurs one patient at a time, often while the clinician is managing meaningful diagnostic uncertainty.

FebriDx introduces another source of information into that decision.

Rather than identifying a specific pathogen, FebriDx measures two host-response biomarkers—myxovirus resistance protein A, or MxA, and C-reactive protein, or CRP—to aid in differentiating bacterial acute respiratory infection from non-bacterial etiology.

The recent CLIA waiver materially changes where that information can potentially be obtained.

FebriDx is FDA 510(k)-cleared and CLIA-waived, allowing the assay to be performed in appropriately authorized waived-testing settings rather than requiring moderate- or high-complexity laboratory certification for this test.

For chief medical officers, antimicrobial stewardship committees, infectious disease leaders, ambulatory medical directors, and laboratory leadership, that regulatory development represents more than a change in laboratory classification.

It creates an opportunity to move objective host-response information much closer to the moment an antibiotic is prescribed—or intentionally not prescribed.

The Diagnostic Gap Behind a Stewardship Problem

Antibiotic stewardship is often discussed as a prescribing problem.

At the point of care, however, it is frequently a diagnostic uncertainty problem first.

A patient with cough, fever, congestion, sore throat, malaise, or other respiratory symptoms may have a presentation compatible with multiple etiologies.

Clinical judgment remains central. But in an ambiguous case, the clinician may still have to decide whether antibacterial therapy is warranted without a definitive answer.

That uncertainty can contribute to empiric or defensive antibiotic prescribing.

This is why stewardship cannot be reduced simply to asking clinicians to prescribe fewer antibiotics.

A more clinically useful question is:

What information can we provide clinicians before they have to make the prescribing decision?

Rapid host-response testing is one potential answer.

What FebriDx Actually Measures

FebriDx is a qualitative, visually interpreted, point-of-care immunoassay performed from a fingerstick blood sample.

It measures two host-response biomarkers:

MxA — Myxovirus Resistance Protein A

MxA is an interferon-inducible protein associated with the antiviral host response. The clinical relevance is not that FebriDx identifies which virus is present, but that MxA provides information about the patient's immune response consistent with viral infection.

CRP — C-Reactive Protein

CRP is an acute-phase protein that increases in response to inflammation, including infection. CRP alone is not specific enough to reliably distinguish bacterial from non-bacterial infection.

The clinical concept behind FebriDx is therefore not based on either biomarker in isolation.

It is the combination of the two host-response signals that provides information intended to help differentiate bacterial acute respiratory infection from non-bacterial etiology. The manufacturer's clinical materials describe this dual-biomarker approach as combining viral host-response information from MxA with inflammatory information from CRP.

FebriDx is instrument-free, self-contained, uses capillary blood obtained by fingerstick, and produces a result after approximately 10 minutes.

The current product materials identify the intended population as patients ages 12 through 64 presenting with acute respiratory infection symptoms for less than seven days and within three days of fever onset.

Those intended-use parameters matter.

CLIA-waived status does not turn FebriDx into a universal respiratory diagnostic. The assay should be used according to its FDA-cleared labeling and Instructions for Use.

Host Response and Pathogen Detection Answer Different Clinical Questions

FebriDx should not be viewed as a replacement for influenza, SARS-CoV-2, RSV, multiplex molecular panels, cultures, or other pathogen-specific diagnostics.

Those tests and FebriDx provide different kinds of information.

Pathogen-directed testing asks:

What organism can be detected?

Host-response testing asks:

What does the patient's immune response suggest about bacterial versus non-bacterial etiology?

That distinction can matter when the central treatment question is not simply whether a particular virus or bacterium is present, but whether antibacterial therapy is warranted.

The manufacturer's own positioning appropriately describes FebriDx as complementary to existing diagnostic pathways. It is not intended to replace clinical judgment, pathogen testing, or clinical guidelines.

For stewardship leaders, that is the most appropriate framework.

FebriDx is not simply another respiratory pathogen test.

It may occupy a different position in the diagnostic pathway.

Why Negative Predictive Value Matters

A central clinical attribute of FebriDx is its performance in supporting rule-out of bacterial infection within its evaluated patient population.

The manufacturer reports a negative predictive value of approximately 99% for ruling out bacterial infection, based on the supporting clinical study population.

That number requires appropriate interpretation.

Negative predictive value is prevalence-dependent.

A 99% NPV should not be interpreted as meaning FebriDx is "99% accurate," nor should a negative result be treated as an absolute guarantee that bacterial infection is absent.

The result must be considered in the context of:

• the population in which the assay was validated,
• pretest probability,
• the patient's clinical presentation,
• other diagnostic findings,
• and the consequences of a false-negative result.

For stewardship purposes, the value is more specific.

In an appropriately selected patient with an uncertain respiratory presentation, a negative result may provide an additional objective data point supporting a decision not to prescribe an antibiotic when the total clinical assessment is consistent with that approach.

That matters because clinicians require confidence not only when prescribing antibiotics, but also when deciding not to prescribe them.

Stewardship Requires Confidence in the Non-Prescribing Decision

One of the practical difficulties in outpatient antibiotic stewardship is that withholding an antibiotic can be more psychologically and operationally difficult than prescribing one.

The clinician may be uncertain.

The patient may expect treatment.

Symptoms may be significant.

Follow-up may be imperfect.

There may be concern about an evolving bacterial process.

A clinician faced with uncertainty may therefore prescribe "just in case," even when bacterial infection is not strongly supported.

An objective result available during the encounter does not eliminate those considerations.

But it can add another clinically relevant piece of evidence to the decision.

That potentially changes the patient conversation as well.

Instead of relying only on:

"I don't think you need an antibiotic,"

the clinician can incorporate an objective host-response result into an explanation of why antibacterial therapy may not be indicated.

The test should not dictate that decision.

It can support it.

What the CLIA Waiver Changes

The CLIA waiver may be the most important implementation development in the evolution of FebriDx.

FebriDx can now be performed in appropriately authorized settings operating under a CLIA Certificate of Waiver. The assay does not require moderate- or high-complexity laboratory certification when performed under the applicable waived-testing framework.

That expands where the technology can potentially fit within a health system.

Depending on the organization's structure and the assay's labeling, appropriate environments may include:

• primary care practices,
• urgent care centers,
• outpatient clinics,
• physician offices,
• emergency departments,
• student health clinics,
• and other qualified point-of-care environments operating under an appropriate CLIA framework.

The key point is not simply that the assay is easier to deploy.

It is that stewardship-supporting information can potentially be moved much closer to the locations where outpatient antibiotics are actually prescribed.

That creates a different implementation model.

CLIA-Waived Does Not Mean Oversight-Free

The term "CLIA-waived" can sometimes be misunderstood.

Waived status does not mean there are no operational responsibilities.

Organizations still need to establish appropriate processes for:

• staff training,
• adherence to the Instructions for Use,
• quality-control procedures,
• documentation,
• result reporting,
• site oversight,
• and compliance with applicable CLIA and organizational policies.

The FebriDx implementation materials specifically describe external positive and negative controls and recommend quality-control testing with new lots, new shipments, and before a new operator performs patient testing. They also outline documentation and record-retention practices for inspection readiness.

This is important for stewardship and laboratory leadership.

The operational advantage of FebriDx is not that quality systems disappear.

It is that the assay can be incorporated into a waived-testing environment without an analyzer or moderate-complexity laboratory infrastructure.

From Retrospective Stewardship to Point-of-Decision Stewardship

Many antimicrobial stewardship interventions occur after prescribing behavior has already occurred.

Programs may analyze prescribing rates.

Review outliers.

Provide clinician education.

Issue guidelines.

Conduct audit and feedback.

Report antibiotic utilization by provider or site.

All of those interventions remain important.

But FebriDx creates the possibility of moving an additional stewardship intervention upstream.

A traditional retrospective pathway might look like:

Patient encounter → diagnostic uncertainty → antibiotic decision → prescribing data → stewardship review → feedback

A point-of-care pathway can potentially look more like:

Patient encounter → diagnostic uncertainty → host-response information → integrated clinical assessment → antibiotic decision

That does not replace traditional stewardship.

It supplements it.

The key difference is timing.

The intervention occurs before the prescription has been written.

The CLIA Waiver Creates a Decentralized Stewardship Opportunity

The more significant opportunity may not be implementation in a single clinic.

It may be deployment across an ambulatory network.

A health system might operate dozens—or hundreds—of locations where respiratory infections are evaluated and antibiotics are prescribed.

Historically, introducing a laboratory diagnostic broadly across those sites could require analyzers, capital investment, calibration, maintenance, connectivity, laboratory staffing, and more complex certification requirements.

FebriDx is self-contained and instrument-free. The implementation materials describe less than one minute of hands-on time, no analyzer, and no routine instrument calibration or maintenance.

CLIA-waived status therefore creates the possibility of deploying a standardized host-response tool across decentralized sites without placing an analyzer at each location.

For a health system pursuing enterprise-wide outpatient stewardship, that deserves consideration.

Antibiotic stewardship increasingly extends beyond the inpatient hospital.

The diagnostic tools supporting stewardship need to extend into those same environments.

Where FebriDx Might Fit in a Clinical Pathway

The most rational implementation is unlikely to involve indiscriminate FebriDx testing of every patient with respiratory symptoms.

A more disciplined strategy would identify where bacterial versus non-bacterial uncertainty is materially influencing treatment decisions.

One potential pathway might be:

Clinical assessment → pathogen-specific testing when clinically indicated → persistent bacterial/non-bacterial uncertainty → FebriDx in an eligible patient → integrated clinical decision

That sequence preserves the distinction between pathogen detection and host-response assessment.

The final step is also critical.

The FebriDx result is one component of the total clinical assessment.

It is not an autonomous treatment instruction.

The manufacturer explicitly positions FebriDx as a decision-support tool that complements clinical judgment rather than replacing it.

That is how an antimicrobial stewardship committee should evaluate it.

The Goal Is Better Antibiotic Use, Not Simply Fewer Antibiotics

Reducing unnecessary antibiotic exposure is a stewardship objective.

But a well-designed program should not define success simply as producing a lower prescribing rate.

The appropriate endpoint is:

Better antibiotic use without compromising patient safety.

That means any implementation should evaluate both stewardship outcomes and balancing measures.

A health system could examine:

• antibiotic prescribing rates,
• clinician-level prescribing variation,
• guideline concordance,
• subsequent bacterial diagnoses,
• return encounters,
• escalation of care,
• emergency department utilization,
• hospitalization,
• provider acceptance,
• patient understanding,
• and workflow impact.

A reduction in antibiotics without appropriate safety monitoring would not constitute a complete stewardship evaluation.

The question is whether the diagnostic information improves decision quality.

Clinical Utility Must Be Demonstrated in Practice

Diagnostic performance alone does not establish clinical utility.

A test can perform well analytically and still have limited impact if:

• clinicians do not trust the result,
• ordering criteria are poorly defined,
• results arrive after the treatment decision,
• workflows are cumbersome,
• or the result rarely changes management.

The CLIA waiver makes the clinical-utility question more relevant because FebriDx can now be moved more directly into the patient encounter.

The manufacturer describes the assay as requiring less than one minute of hands-on time, with the result available after approximately 10 minutes.

For implementation teams, the key operational question becomes:

Can the result reliably be available before the clinician makes the antibiotic decision?

If not, the clinical value of a rapid test may be substantially reduced.

What FebriDx Does—and Does Not—Tell the Clinician

A responsible stewardship implementation should define the limitations of the assay explicitly.

FebriDx does not identify a specific pathogen.

It does not eliminate the need for pathogen-directed testing when pathogen identification is clinically necessary.

It does not replace history, physical examination, imaging, microbiology, or other laboratory testing when indicated.

It does not establish severity of illness.

It does not mean every non-bacterial result should automatically lead to antibiotic avoidance.

And it should not be used outside its authorized intended-use population.

FebriDx provides another piece of host-response information for the clinician to integrate into the total clinical picture.

The manufacturer's compliance guidance appropriately prohibits claims that FebriDx diagnoses specific pathogens, replaces clinical judgment, eliminates other testing, guarantees reimbursement, or reduces antibiotic use in every case.

That restraint actually strengthens the clinical case.

The value proposition does not require overstating what the assay does.

A Stewardship Committee Should Evaluate FebriDx as a Clinical Intervention

The most productive question for a stewardship committee may not be:

"Should we add another respiratory test?"

It may be:

"Where in our system are clinicians making antibiotic decisions under avoidable diagnostic uncertainty, and could host-response testing improve those decisions?"

That leads naturally to a prospective evaluation.

A health system could identify high-volume respiratory settings, establish baseline prescribing patterns, define appropriate patient-selection criteria, implement FebriDx within a controlled workflow, and measure both stewardship outcomes and patient-safety outcomes.

Metrics Worth Measuring

A serious evaluation could include:

Antibiotic prescribing rate

Does antibiotic utilization change among appropriately selected FebriDx-tested patients?

Provider variation

Does access to objective host-response information reduce unwarranted variation between clinicians or sites?

Safety

Are there changes in repeat evaluation, delayed bacterial diagnoses, escalation of care, emergency department visits, hospitalization, or other clinically important balancing measures?

Diagnostic utilization

Does FebriDx affect use of pathogen testing, imaging, laboratory testing, or other diagnostics?

Workflow

Is the result consistently available before the treatment decision?

Clinician acceptance

Do clinicians believe the result improves decision-making in ambiguous cases?

Patient communication

Does objective testing help clinicians explain antibiotic-prescribing or non-prescribing decisions?

Guideline concordance

Does adoption improve alignment between prescribing behavior and the organization's stewardship protocols?

Those measures allow leadership to determine whether FebriDx is actually changing care—not merely whether the test is being ordered.

The Opportunity for Standardization

Another potential advantage for health systems is standardization.

Antibiotic decision-making can vary substantially between providers, locations, and shifts.

Some variation is clinically appropriate.

Some may reflect differences in tolerance for uncertainty.

A point-of-care host-response assay introduces the possibility of giving clinicians across multiple locations access to the same additional objective data.

That does not standardize medical judgment.

It may help standardize the information available to inform it.

For a stewardship program operating across a large ambulatory network, that distinction can be meaningful.

Why This Matters to the Chief Medical Officer

For a chief medical officer, FebriDx sits at the intersection of several priorities.

Clinical quality

Supporting more evidence-informed antibiotic decision-making.

Patient safety

Reducing avoidable antibiotic exposure while maintaining vigilance for bacterial disease.

Antimicrobial stewardship

Moving part of the stewardship intervention closer to the actual prescribing decision.

Clinical standardization

Providing a common diagnostic tool across decentralized sites where respiratory infections are treated.

Physician support

Giving clinicians additional objective information rather than simply asking them to change prescribing behavior.

Patient communication

Providing another evidence point that may help explain why an antibiotic is—or is not—appropriate.

Operational scalability

Deploying an instrument-free assay across waived-testing environments without requiring an analyzer at every site.

Most importantly, FebriDx represents a stewardship strategy that does not depend solely on policies, guidelines, or retrospective feedback.

It attempts to improve the information available at the point of care.

That is a fundamentally different intervention.

Why the CLIA Waiver Changes the Implementation Conversation

The biological premise of FebriDx did not change when the assay became CLIA-waived.

The stewardship problem did not change.

What changed was the practical ability to deploy the test across a broader range of point-of-care environments.

That matters because a diagnostic cannot influence a prescribing decision if it cannot practically be placed where the prescribing decision occurs.

CLIA-waived status allows FebriDx to be implemented under a Certificate of Waiver in authorized settings and removes the need for moderate- or high-complexity laboratory certification for this assay.

The result is a potentially different model of diagnostic stewardship:

not simply better testing inside the laboratory,

but clinically useful testing distributed across the healthcare system.

From Antibiotic Stewardship Policy to Diagnostic Stewardship Infrastructure

Antimicrobial stewardship has appropriately emphasized accountability, guidelines, education, audit and feedback, prescribing measurement, and clinician engagement.

The next stage may increasingly involve diagnostic stewardship infrastructure capable of delivering relevant information at the moment treatment decisions are made.

FebriDx represents one example of that evolution.

It does not solve every respiratory diagnostic question.

It does not identify the pathogen.

It does not replace the clinician.

It does not provide an automatic answer regarding antibiotic therapy.

Its potential value is narrower—and potentially important.

It provides an additional, rapidly available host-response signal intended to help differentiate bacterial acute respiratory infection from non-bacterial etiology while the patient is still being evaluated.

With CLIA-waived status reducing an important implementation barrier, healthcare organizations now have an opportunity to determine whether that information can improve antibiotic decision-making within their own clinical environments.

For CMOs and antimicrobial stewardship committees, the appropriate next step is not to assume that FebriDx will transform prescribing.

It is to evaluate whether it can—prospectively, rigorously, and with both stewardship and patient-safety outcomes measured.

That is how a diagnostic moves beyond simply being another test.

It becomes part of the clinical infrastructure supporting better decisions.

About FebriDx

FebriDx is an FDA 510(k)-cleared, CLIA-waived, prescription-use point-of-care assay that measures the host-response biomarkers MxA and CRP from fingerstick blood to aid in differentiating bacterial acute respiratory infection from non-bacterial etiology.

The current product materials specify use in patients ages 12 through 64 presenting with symptoms of acute respiratory infection for less than seven days and within three days of fever onset.

About CG Moneta Consulting

CG Moneta Consulting works with healthcare organizations to evaluate and implement clinical, operational, financial, and technology solutions designed to improve healthcare delivery.

Through its strategic relationships, CGM supports healthcare organizations evaluating FebriDx and its potential role within point-of-care respiratory diagnostics and antimicrobial stewardship programs.

Clinical and Regulatory Note

FebriDx should be used in accordance with its FDA-cleared labeling and Instructions for Use. Results are intended to support—not replace—clinical judgment and should be interpreted in the context of the patient's presentation and other clinically appropriate diagnostic information. CLIA-waived sites remain responsible for applicable training, quality-control, documentation, oversight, and compliance requirements.

Selected References

Shapiro NI, Filbin MR, Hou PC, et al. Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting. JAMA Network Open. 2022;5(10):e2234588. The FebriDx materials cite this multicenter study as supporting the assay's bacterial versus non-bacterial performance.

Lumos Diagnostics / PHASE Scientific Americas. FebriDx practitioner, clinical, regulatory, and CLIA-waived implementation materials.

U.S. Food and Drug Administration. FebriDx Bacterial/Non-bacterial Assay, 510(k) clearance K260787.

Centers for Disease Control and Prevention. Outpatient antibiotic stewardship and antimicrobial-resistance guidance.